Brokerages Set Certara, Inc. (NASDAQ:CERT) PT at $15.83

Certara, Inc. (NASDAQ:CERT) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $15.83.

Several equities analysts have weighed in on CERT shares. Barclays increased their price objective on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. William Blair restated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Finally, TD Cowen began coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 target price for the company.

Certara Stock Performance

NASDAQ CERT opened at $10.15 on Monday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The company has a market capitalization of $1.63 billion, a PE ratio of -50.75, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. Certara has a 52-week low of $9.41 and a 52-week high of $19.18. The company has a 50-day simple moving average of $12.50 and a 200 day simple moving average of $11.46.

Institutional Investors Weigh In On Certara

A number of institutional investors and hedge funds have recently modified their holdings of the company. Blue Trust Inc. grew its stake in Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after acquiring an additional 822 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Certara by 3.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company’s stock valued at $253,000 after purchasing an additional 823 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after purchasing an additional 1,047 shares during the period. Nicolet Advisory Services LLC raised its position in shares of Certara by 6.6% in the third quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company’s stock worth $273,000 after buying an additional 1,531 shares in the last quarter. Finally, KBC Group NV boosted its stake in Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after buying an additional 1,584 shares during the period. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.